Alzheimer Disease
📧 Sign up to get email alerts when something new happens for Alzheimer Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2013-10-25FDA Approved: VIZAMYL — Original Application (GE Healthcare Inc. (Medi-Physics, Inc. dba GE Healthcare))
FDA approved Vizamyl (flutemetamol F-18) under an original application as a PET imaging agent to detect beta-amyloid plaques in adult patien…
-
FDA approval · 2013-10-25FDA Approved: AMYVID — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for AMYVID (Florbetapir F-18) submitted by Eli Lilly and Company.
-
FDA approval · 2013-10-24FDA Approved: MEMANTINE HYDROCHLORIDE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for memantine hydrochloride from Actavis Pharma, Inc. This action supplements the existing approval …
-
CLINICAL_TRIALS research · 2013-10-16Clinical Trial Update: Alzheimer's Family Research
A completed clinical trial update from University of California, San Francisco on Alzheimer's disease family research focusing on decision-m…
-
FDA approval · 2013-09-20FDA Approved: DONEPEZIL HYDROCHLORIDE — Supplemental Application (ACI Healthcare USA, Inc.)
FDA approved a supplemental application for donepezil hydrochloride (ACI Healthcare USA, Inc.), approving changes to the drug's labeling und…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA guidance · 2013-09-20World Alzheimer's Month - Supporting development of medicines by qualification of biomarkers
EMA discusses aiding the development of medicines by qualifying biomarkers, highlighting regulatory qualification processes during World Alz…
-
CLINICAL_TRIALS trial_result · 2013-09-19Clinical Trial Update: A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD) [Phase 2, Phase 3]
This is a Phase II/III trial update of Florbetapir (18F) PET imaging conducted in Japan across healthy volunteers, mild cognitive impairment…
-
CLINICAL_TRIALS trial_result · 2013-09-19Clinical Trial Update: A Study of Florbetapir (18F) in Japanese Healthy Volunteers [Phase 1]
Phase 1 study evaluating florbetapir F-18 in Japanese healthy volunteers; results were posted after completion in 2013.
-
CLINICAL_TRIALS trial_result · 2013-09-18Clinical Trial Update: Effects of Exercise and Cognitive Training on Cognitive Function in Older Adults [NA]
A Cleveland Clinic-sponsored clinical trial evaluating the impact of exercise and cognitive training on cognitive function in older adults h…
-
CLINICAL_TRIALS trial_result · 2013-09-12Clinical Trial Update: Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease [NA]
A terminated Pfizer-sponsored trial evaluated the acute effects of donepezil on brain perfusion and memory in people with cognitive impairme…
-
CLINICAL_TRIALS trial_result · 2013-09-12Clinical Trial Update: Zydena on Cognitive Function of Alzheimer's Disease Patients [Phase 3]
A Phase 3 clinical trial evaluating Zydena for cognitive function in Alzheimer's disease is in progress. The current status of the trial is …
-
FDA approval · 2013-09-06FDA Approved: ARICEPT — Supplemental Application (Eisai Inc.)
The FDA approved Eisai's supplemental application for Aricept (donepezil hydrochloride).
-
FDA approval · 2013-09-06FDA Approved: ARICEPT — Supplemental Application (Eisai Inc.)
FDA approved a supplemental application for ARICEPT (donepezil hydrochloride) submitted by Eisai Inc.
-
CLINICAL_TRIALS trial_result · 2013-09-04Clinical Trial Update: Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease [Phase 1]
A Phase 1 multiple ascending dose study of TC-5619 in healthy elderly subjects and individuals with Alzheimer's disease has completed.
-
CLINICAL_TRIALS trial_result · 2013-09-02Clinical Trial Update: A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease [Phase 3]
A Phase 3 trial of galantamine for mild to moderate Alzheimer's disease was terminated, with results posted in 2013.
-
CLINICAL_TRIALS trial_result · 2013-08-29Clinical Trial Update: Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort [Phase 1]
Phase 1 study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of the investigational agent E2609 in healthy subjects…
-
CLINICAL_TRIALS trial_result · 2013-08-14Clinical Trial Update: The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease [Phase 4]
A Phase 4 trial evaluating the efficacy of a combination regimen in patients with mild to moderate probable Alzheimer's disease has been com…
-
FDA approval · 2013-08-05FDA Approved: CERETEC — Supplemental Application (Medi-Physics Inc. dba GE Healthcare.)
FDA approves a supplemental application for CERETEC (TECHNETIUM TC-99M EXAMETAZIME) from Medi-Physics Inc. dba GE Healthcare.
-
CLINICAL_TRIALS trial_result · 2013-08-05Clinical Trial Update: A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease
A completed study investigating whether changes in attention with galantamine treatment correlate with changes in caregiver burden in Alzhei…
-
CLINICAL_TRIALS trial_result · 2013-08-01Clinical Trial Update: Efficacy Assessment of Three Non Pharmacological Therapies in Alzheimer's Disease [Phase 3]
Phase 3 trial assessing the efficacy of three non-pharmacological therapies for Alzheimer's disease has been completed. The document provide…
-
CLINICAL_TRIALS trial_result · 2013-07-31Clinical Trial Update: Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers [Phase 1]
Phase 1 trial update evaluating the PET radioligand BAY85-8102 F-18 (DPA-714) for neuroinflammation in probable Alzheimer's disease patients…
-
FDA approval · 2013-07-25FDA Approved: DONEPEZIL HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for donepezil hydrochloride from Rising Pharma Holdings, Inc., related to an approved product (speci…
-
FDA approval · 2013-07-24FDA Approved: DONEPEZIL HYDROCHLORIDE — Original Application (Dr. Reddys Laboratories Limited)
FDA approved the original application for a generic donepezil hydrochloride product from Dr. Reddy's Laboratories Limited, enabling a generi…
-
CLINICAL_TRIALS trial_result · 2013-07-19Clinical Trial Update: A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808 [EARLY_Phase 1]
A Phase 0, open-label, multi-center exploratory safety study of [F-18]T808 for Alzheimer's disease has been terminated.
-
CLINICAL_TRIALS research · 2013-07-19Clinical Trial Update: A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807 [EARLY_Phase 1]
The trial update reports termination of a Phase 0, open-label exploratory safety study of [F-18]T807 (AV-1451/Flortaucipir) in Alzheimer's d…